Impact BioMedical Inc. (IBO)
NYSEAMERICAN: IBO · Real-Time Price · USD
0.5069
+0.0132 (2.67%)
Sep 10, 2026, 11:29 AM EDT - Market open
Impact BioMedical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.04 | 0.03 | - | - | 0.05 | - | |
Revenue Growth | 400.00% | - | - | - | - | - |
Cost of Revenue | 0.42 | 0.42 | - | - | - | - |
Gross Profit | -0.39 | -0.39 | - | - | 0.05 | - |
Selling, General & Admin | 2.96 | 1.98 | 1.83 | 1.1 | 1.12 | 0.99 |
Research & Development | 0.29 | 0.34 | 0.28 | 1.69 | 1.23 | 1.08 |
Other Operating Expenses | 0.32 | 0.42 | 0.17 | 0.12 | - | - |
Operating Expenses | 4.71 | 3.88 | 3.4 | 4.03 | 3.45 | 3.19 |
Operating Income | -5.1 | -4.27 | -3.4 | -4.03 | -3.4 | -3.19 |
Interest Expense | -0.26 | -0.79 | -1.07 | -0.44 | -0.46 | -0.3 |
Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.17 |
Other Non Operating Income (Expenses) | 3.55 | -9.39 | 5.07 | 0.05 | 0.07 | 0.08 |
EBT Excluding Unusual Items | -1.79 | -14.44 | 0.62 | -4.41 | -3.78 | -3.24 |
Impairment of Goodwill | - | - | -25.09 | - | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -4.1 | - |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | - | - | - | - |
Asset Writedown | - | - | -0.26 | - | - | - |
Pretax Income | -1.8 | -14.45 | -24.74 | -4.41 | -7.88 | -3.24 |
Income Tax Expense | -2.58 | -2.58 | 0.03 | - | -0.62 | -1.4 |
Earnings From Continuing Operations | 0.78 | -11.87 | -24.77 | -4.41 | -7.26 | -1.85 |
Minority Interest in Earnings | 0.01 | 0.03 | 0.06 | 0.07 | 0.2 | 0.55 |
Net Income | 0.79 | -11.84 | -24.71 | -4.34 | -7.05 | -1.3 |
Net Income to Common | 0.79 | -11.84 | -24.71 | -4.34 | -7.05 | -1.3 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 79 | 32 | 11 | 60 | 70 | 70 |
Shares Outstanding (Diluted) | 79 | 32 | 11 | 60 | 70 | 70 |
Shares Change | 571.61% | 193.30% | -82.14% | -14.54% | - | - |
EPS (Basic) | 0.01 | -0.38 | -2.30 | -0.07 | -0.10 | -0.02 |
EPS (Diluted) | 0.01 | -0.38 | -2.30 | -0.07 | -0.10 | -0.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -0.51 | -1.89 | -2.85 | -2.87 | -2.52 | -2.03 |
Free Cash Flow Per Share | -0.01 | -0.06 | -0.27 | -0.05 | -0.04 | -0.03 |
Gross Margin | - | - | - | - | 100.00% | - |
Operating Margin | -14557.14% | -13343.75% | - | - | -6808.00% | - |
Profit Margin | 2260.00% | -36993.75% | - | - | -14102.00% | - |
Free Cash Flow Margin | -1451.43% | -5906.25% | - | - | -5036.00% | - |
EBITDA | -3.95 | -3.13 | -3.39 | -4.02 | -2.29 | -2.07 |
D&A For EBITDA | 1.14 | 1.15 | 0.01 | 0.01 | 1.11 | 1.11 |
EBIT | -5.1 | -4.27 | -3.4 | -4.03 | -3.4 | -3.19 |
Revenue as Reported | 0.04 | 0.03 | - | - | - | - |